CK Hutchison Holdings 주식 (OTC: CKHUY)

에 대한 최신 뉴스 CK Hutchison Holdings (OTC:CKHUY) 주식

CK Hutchison Holdings, or CKH, is a Hong Kong headquartered conglomerate with key businesses in ports, retail, infrastructure, and telecommunications. The company was created in 2015 to house the merged assets of Cheung Kong Holdings and Hutchison Whampoa as the group sought to flatten out and simplify its original holding structure. CKH contains most of the businesses previously housed in Hutchison Whampoa, minus the property assets, which were spun off into their own listing, CK Asset Holdings. Telecommunications and infrastructure activities now make up the largest share of EBITDA, at around 53%.

Equities

Politics

Markets

General

CKHUY

국무장관 마코 루비오의 파나마 방문은 트럼프 행정부 하에서 미국 외교 정책, 특히 라틴 아메리카에 대한 방향성에 중요한 통찰을 제공할 것으로 예상된다. 파나마 운하를 둘러싼 긴장이 고조되는 가운데, 이번 방문은 미국 정책이 보다 공격적이고 제국주의적인 접근을 취할 것인지, 아니면 실용적이고 협상 중심의 입장을 취할 것인지를 신호할 수 있다고 로이터 통신이 보도했다.

마코 루비오의 파나마 방문: 트럼프의 공격적 언변이 전쟁 또는 외교로 이끌 것인가?

CK HUTCH HLD LTD UNSP/ADR by CK Hutchison Holdings LTD

CK Hutchison Holdings Ltd

<p>Deep-pocketed investors have adopted a bearish approach towards Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DG usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Dollar Gen. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 25% leaning bullish and 62% bearish. Among these notable options, 6 are puts, totaling $201,510, and 2 are calls, amounting to $69,050.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $60.0 to $85.0 for Dollar Gen over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Dollar Gen's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Dollar Gen's substantial trades, within a strike price spectrum from $60.0 to $85.0 over the preceding 30 days.</p>
<h3>Dollar Gen Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741288648_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$6.85</td>
<td>$6.8</td>
<td>$6.8</td>
<td>$75.00</td>
<td>$43.5K</td>
<td>648</td>
<td align="right">167</td>
</tr>
<tr>
<td>DG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.55</td>
<td>$5.45</td>
<td>$5.55</td>
<td>$70.00</td>
<td>$36.0K</td>
<td>1.7K</td>
<td align="right">66</td>
</tr>
<tr>
<td>DG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$17.7</td>
<td>$17.3</td>
<td>$17.7</td>
<td>$85.00</td>
<td>$35.4K</td>
<td>1.4K</td>
<td align="right">24</td>
</tr>
<tr>
<td>DG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$3.8</td>
<td>$3.6</td>
<td>$3.75</td>
<td>$60.00</td>
<td>$35.2K</td>
<td>749</td>
<td align="right">341</td>
</tr>
<tr>
<td>DG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.55</td>
<td>$5.45</td>
<td>$5.55</td>
<td>$70.00</td>
<td>$34.9K</td>
<td>1.7K</td>
<td align="right">132</td>
</tr>
</tbody>
</table>
</p>
<h3>About Dollar Gen</h3>
<p>With more than 20,000 locations, Dollar General's banner is nearly ubiquitous across the rural United States. Dollar General serves as a convenient shopping destination for fill-in store trips, with its value proposition most relevant to consumers in small communities with a dearth of shopping options. The retailer operates a frugal store of about 7,500 square feet and primarily offers an assortment of branded and private-label consumable items (80% of net sales) such as paper and cleaning products, packaged and perishable food, and health and beauty items at low prices. Dollar General also offers a limited assortment of seasonal merchandise, home products, and apparel. The firm sells most items at a price point of $10 or less.</p>
<p>Following our analysis of the options activities associated with Dollar Gen, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Dollar Gen</h3>
<ul>
<li>Trading volume stands at 1,482,950, with DG's price up by 2.54%, positioned at $75.57.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 7 days.</li>
</ul>
<h3>Professional Analyst Ratings for Dollar Gen</h3>
<p>Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $86.67.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Telsey Advisory Group persists with their Market Perform rating on Dollar Gen, maintaining a target price of $85.<br />
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Dollar Gen, which currently sits at a price target of $95.<br />
&#x2A; An analyst from Deutsche Bank downgraded its action to Hold with a price target of $80. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Dollar Gen, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Smart Money Is Betting Big In Dollar Gen Options

<p>Deep-pocketed investors have adopted a bullish approach towards Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CAVA usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Cava Group. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 53% leaning bullish and 40% bearish. Among these notable options, 5 are puts, totaling $279,455, and 10 are calls, amounting to $885,741.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $150.0 for Cava Group over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Cava Group's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Cava Group's significant trades, within a strike price range of $60.0 to $150.0, over the past month.</p>
<h3>Cava Group Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741288643_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$33.35</td>
<td>$32.55</td>
<td>$33.35</td>
<td>$60.00</td>
<td>$226.7K</td>
<td align="right">777</td>
<td align="right">68</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$37.7</td>
<td>$36.65</td>
<td>$37.7</td>
<td>$65.00</td>
<td>$188.5K</td>
<td align="right">13</td>
<td align="right">0</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$32.65</td>
<td>$32.15</td>
<td>$32.65</td>
<td>$75.00</td>
<td>$159.9K</td>
<td align="right">108</td>
<td align="right">49</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$17.5</td>
<td>$17.5</td>
<td>$17.5</td>
<td>$95.00</td>
<td>$87.5K</td>
<td align="right">476</td>
<td align="right">50</td>
</tr>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$26.5</td>
<td>$25.85</td>
<td>$26.2</td>
<td>$110.00</td>
<td>$78.6K</td>
<td align="right">800</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Cava Group</h3>
<p>Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates all of its revenue from the CAVA segment.</p>
<p>Following our analysis of the options activities associated with Cava Group, we pivot to a closer look at the company's own performance.</p>
<h3>Cava Group's Current Market Status</h3>
<ul>
<li>Trading volume stands at 2,312,033, with CAVA's price down by -4.63%, positioned at $82.74.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 82 days.</li>
</ul>
<h3>Professional Analyst Ratings for Cava Group</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $121.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Loop Capital continues to hold a Hold rating for Cava Group, targeting a price of $100.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Cava Group with a target price of $104.<br />
&#x2A; Reflecting concerns, an analyst from Wedbush lowers its rating to Outperform with a new price target of $150.<br />
&#x2A; An analyst from Piper Sandler upgraded its action to Overweight with a price target of $115.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Cava Group, targeting a price of $140. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Cava Group, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


CAVA

Unpacking the Latest Options Trading Trends in Cava Group

<p>Deep-pocketed investors have adopted a bullish approach towards AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AZO usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for AutoZone. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 41% leaning bullish and 8% bearish. Among these notable options, 5 are puts, totaling $332,750, and 7 are calls, amounting to $324,653.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $2800.0 to $4000.0 for AutoZone over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for AutoZone's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AutoZone's whale trades within a strike price range from $2800.0 to $4000.0 in the last 30 days. </p>
<h3>AutoZone 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741288638_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AZO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$103.0</td>
<td>$100.0</td>
<td>$100.0</td>
<td>$3600.00</td>
<td>$100.0K</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>AZO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$474.0</td>
<td>$471.0</td>
<td>$471.0</td>
<td>$4000.00</td>
<td>$94.2K</td>
<td align="right">3</td>
<td align="right">2</td>
</tr>
<tr>
<td>AZO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$841.7</td>
<td>$827.5</td>
<td>$840.0</td>
<td>$2800.00</td>
<td>$84.0K</td>
<td align="right">8</td>
<td align="right">1</td>
</tr>
<tr>
<td>AZO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$757.0</td>
<td>$744.2</td>
<td>$750.0</td>
<td>$2900.00</td>
<td>$75.0K</td>
<td align="right">12</td>
<td align="right">1</td>
</tr>
<tr>
<td>AZO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$64.0</td>
<td>$55.1</td>
<td>$59.5</td>
<td>$3500.00</td>
<td>$59.5K</td>
<td align="right">5</td>
<td align="right">13</td>
</tr>
</tbody>
</table>
</p>
<h3>About AutoZone</h3>
<p>AutoZone operates as a leading retailer of aftermarket automotive parts in the United States. The firm operates more than 6,400 stores domestically, serving both the do-it-yourself and commercial (do-it-for-me) end markets. Through its vast store footprint and distribution network, AutoZone manages a wide array of stock-keeping units applicable to numerous vehicle makes and models, providing its consumers with ample product availability. The firm drives traffic by providing superior and convenient customer service as AutoZone's team of knowledgeable staff assists consumers with diagnosing a vehicle's problem, selecting the necessary part for replacement, and in some instances, installation. The company also operates internationally, with 800 stores in Mexico and more than 100 in Brazil.</p>
<h3>Current Position of AutoZone</h3>
<ul>
<li>With a volume of 85,033, the price of AZO is up 0.14% at $3561.03. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 75 days.</li>
</ul>
<h3>What Analysts Are Saying About AutoZone</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $3718.2.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from B of A Securities persists with their Neutral rating on AutoZone, maintaining a target price of $3700.<br />
&#x2A; Maintaining their stance, an analyst from BMO Capital continues to hold a Outperform rating for AutoZone, targeting a price of $3850.<br />
&#x2A; In a cautious move, an analyst from Wedbush downgraded its rating to Outperform, setting a price target of $3700.<br />
&#x2A; An analyst from DA Davidson persists with their Neutral rating on AutoZone, maintaining a target price of $3500.<br />
&#x2A; An analyst from Truist Securities persists with their Buy rating on AutoZone, maintaining a target price of $3841. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for AutoZone, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Decoding AutoZone's Options Activity: What's the Big Picture?

<p>The National Institute for Health and Care Excellence (NICE) has reaffirmed its stance against recommending Alzheimer&#8217;s treatments donanemab and lecanemab for NHS use, citing <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">insufficient cost-effectiveness</a>.</p>
<p>Despite additional evidence submitted by manufacturers, the independent appraisal committee <a target="_blank" href="https://www.nice.org.uk/news/articles/second-consultation-launched-on-nhs-funding-for-alzheimer-s-treatments" rel="noreferrer noopener">concluded</a> that the treatments do not provide enough benefit to justify their significant cost.</p>
<p>NICE first raised concerns about these treatments last year, determining that their clinical benefits did not outweigh the financial burden they would place on the NHS.</p>
<p><strong>Read Next: <a target="_blank" href="https://www.benzinga.com/25/03/44171941/denali-therapeutics-ends-als-trial-extension-analyst-stays-optimistic-despite-trial-setback" rel="noreferrer noopener">Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback</a></strong></p>
<p>Although the U.K.&#8217;s Medicines and Healthcare Products Regulatory Agency (MHRA) approved Eli Lilly&#8217;s Kisunla (donanemab) in October, NICE <a target="_blank" href="https://www.benzinga.com/top-stories/24/10/41498770/eli-lilly-alzheimers-drug-faces-tough-road-in-uk-price-watchdog-nice-says-donanemab-is-not-cost-effe" rel="noreferrer noopener">refused&nbsp;to cover it</a>.</p>
<p>The agency ruled that the cost of providing donanemab balanced against the relatively small benefit cannot currently be considered good value for the taxpayer.</p>
<p>In August, MHRA approved <strong>Biogen Inc&#8217;s</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40514109/biogens-alzheimers-drug-secures-uk-approval-but-an-independent-agency-does-not-recommend-reimburs" rel="noreferrer noopener">Leqembi (lecanemab)</a>.</p>
<p>Despite the approval, NICE said in its guidance draft,&#8221;&nbsp;benefits of the new Alzheimer&#8217;s drug lecanemab are too small to justify the costs.&#8221;</p>
<p>Following a request for further data, the latest assessment has reinforced that donanemab and lecanemab remain economically unviable for NHS funding.</p>
<p>&#8220;Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab,&#8221; the agency says in its statement.</p>
<p>Stakeholders are encouraged to contribute their perspectives before the consultation period closes on March 27, 2025.</p>
<p>A third committee meeting will review all responses and additional analyses before NICE issues its final recommendations.</p>
<p><strong>Price Action:</strong> At the last check on Thursday, BIIB stock was up 1.50% at $145.92, and LLY stock was down 2.82% at $903.84.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/equities/25/03/44170118/meet-magic-apron-home-depot-launches-generative-ai-tool-to-enhance-spring-shopping" target="_blank" rel="noreferrer noopener">Meet Magic Apron: Home Depot Launches Generative AI Tool To Enhance Spring Shopping</a></strong></li>
</ul>
<p><em>Photo via Shutterstock</em></p>


Biotech

Government

Large Cap

News

Health Care

BIIB

Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding

<p>Despite <strong>Dogecoin's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) lackluster performance, whale investors are aggressively accumulating DOGE ahead of <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44125213/white-house-crypto-summit-to-feature-roundtable-with-industry-leaders-including-michael-saylor">Friday&#8217;s crypto summit</a>.</p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>24-Hour Trend</strong></td>
<td><strong>7-Day Trend</strong></td>
</tr>
<tr>
<td><strong>Dogecoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2010</td>
<td>$29.8 billion</td>
<td>-0.5%</td>
<td>-3.7%</td>
</tr>
<tr>
<td><strong>Shiba Inu</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001317</td>
<td>$7.8 billion</td>
<td>+0.3%</td>
<td>-9.4%</td>
</tr>
<tr>
<td><strong>PEPE</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>$0.0<sub>5</sub>6803 &nbsp;</td>
<td>$2.9 billion</td>
<td>-2.7%</td>
<td>-18.8%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Trader Notes: </strong>In an X <a href="https://x.com/ali_charts/status/1897396450528809329">post</a> on Thursday, Crypto chart analyst Ali Martinez highlighted that DOGE is trading within an ascending parallel channel. If the $0.16 support level holds, a rally toward the mid-channel at $2.74 or even the upper boundary at $6.24 remains possible.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> <a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> remains within an ascending parallel channel. As long as the lower boundary at $0.16 holds, a rebound toward the mid-channel at $2.74 or even the upper boundary at $6.24 remains a probability! <a href="https://t.co/L0p9ePH5ZV">pic.twitter.com/L0p9ePH5ZV</a></p>
<p>&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1897396450528809329?ref_src=twsrc%5Etfw">March 5, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>In another <a href="https://x.com/ali_charts/status/1897582425611604128">tweet</a>, Martinez warned that if DOGE fails to hold this level, it could crash significantly. </p>
<p>DOGE has tended to rebound from this channel since 2014 towards the upward resistance trend line. </p>
<p>A break below $0.19 could trigger a sharp correction toward $0.015.</p>
<p><strong>Statistics</strong>: Martinez <a href="https://x.com/ali_charts/status/1897700957103837293">cited</a> Santiment data to show whales purchased 150 million DOGE in the last 72 hours.</p>
<p>Coinglass data shows Dogecoin liquidations in the past 24 hours stood at $6.5 million, while open interest increased 2.4% to $1.8 billion. DOGE Derivatives trading volume expanded 12.9% to $3.08 billion.</p>
<p><strong>What's Next: </strong>With rising whale activity, increasing open interest, and the upcoming White House event, DOGE could be setting up for a major move—but whether that's a breakout or breakdown depends on key support levels.</p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44145377/dogecoin-indicators-flash-oversold-conditions-is-it-time-to-accumulate">Dogecoin Indicators Flash Oversold Conditions: Is It Time To Accumulate?</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Dogecoin Whales Accumulating 150 Million Despite Price Drop: What Do They Know?

<p>Needham  analyst Joseph Stringer   reiterates Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) with a Buy and maintains $28 price target.</p>


Price Target

Reiteration

Analyst Ratings

PHAT

Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target

<p>Needham  analyst Serge Belanger   reiterates Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.</p>


CLSD

Needham Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target

<p>10 analysts have shared their evaluations of Northern Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRS#NASDAQ">NTRS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Northern Trust, revealing an average target of $118.5, a high estimate of $136.00, and a low estimate of $102.00. Marking an increase of 5.07%, the current average surpasses the previous average price target of $112.78. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741287787_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Northern Trust. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$136.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$114.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$116.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>David Konrad</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$122.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$102.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Hold</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$118.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$125.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$127.00</td>
<td>$103.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Northern Trust. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Northern Trust compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Northern Trust's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Northern Trust's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NTRS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Northern Trust analyst ratings.</strong></a></p>
<h2>About Northern Trust</h2>
<p>Northern Trust is a leading provider of wealth management, asset servicing, asset management, and banking to corporations, institutions, affluent families, and individuals. Founded in Chicago in 1889, Northern Trust has offices in 20 states and Washington, D.C. as well as 23 locations in Canada, Europe, the Middle East, and Asia-Pacific. As of September 2024, Northern Trust had assets under custody or administration of $17.4 trillion and assets under management of $1.6 trillion.</p>
<h3>Key Indicators: Northern Trust's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Northern Trust displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>26.81%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Northern Trust's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>22.81%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>3.76%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Northern Trust's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.29%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.12</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NTRS

10 Analysts Assess Northern Trust: What You Need To Know

<p>15 analysts have expressed a variety of opinions on Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">3</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $37.07, along with a high estimate of $68.00 and a low estimate of $21.00. Witnessing a positive shift, the current average has risen by 38.89% from the previous average price target of $26.69.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741287773_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Hims &amp; Hers Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Maintains</td>
<td>Sell</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$39.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$40.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$61.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Sell</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$21.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Maria Ripps</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$68.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$60.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Sell</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>David Larsen</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$42.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hims &amp; Hers Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Hims &amp; Hers Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Hims &amp; Hers Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Hims &amp; Hers Health's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HIMS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Hims &amp; Hers Health analyst ratings.</strong></a></p>
<h2>Delving into Hims &amp; Hers Health's Background</h2>
<p>Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.</p>
<h3>Understanding the Numbers: Hims &amp; Hers Health's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Hims &amp; Hers Health's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>95.09%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Hims &amp; Hers Health's net margin excels beyond industry benchmarks, reaching <strong>5.41%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Hims &amp; Hers Health's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>5.68%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Hims &amp; Hers Health's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>3.97%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Hims &amp; Hers Health's debt-to-equity ratio is below the industry average. With a ratio of <b>0.02</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Hims & Hers Health, Inc. Class A Common Stock

HIMS

Forecasting The Future: 15 Analyst Projections For Hims & Hers Health

<p>HC Wainwright &amp; Co.  analyst Yi Chen   reiterates Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.</p>


HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target

<p>During the last three months, 10 analysts shared their evaluations of Health Catalyst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $7.7, along with a high estimate of $10.00 and a low estimate of $5.00. Experiencing a 19.88% decline, the current average is now lower than the previous average price target of $9.61. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741287758_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A clear picture of Health Catalyst's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$5.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.50</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$9.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Health Catalyst. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Health Catalyst compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Health Catalyst's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Health Catalyst's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HCAT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Health Catalyst analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Delving into Health Catalyst's Background</h2>
<p>Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.</p>
<h3>Financial Insights: Health Catalyst</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Health Catalyst's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>6.02%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Health Catalyst's net margin is impressive, surpassing industry averages. With a net margin of <strong>-25.97%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Health Catalyst's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-5.74%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Health Catalyst's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-2.47%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Health Catalyst's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>1.1</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


HCAT

10 Analysts Have This To Say About Health Catalyst

<p>Ratings for Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Plug Power, revealing an average target of $1.81, a high estimate of $3.00, and a low estimate of $1.00. This current average has decreased by 26.72% from the previous average price target of $2.47. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741287748_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of Plug Power by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthur Sitbon</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$1.60</td>
<td>$1.75</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$1.25</td>
<td>$2.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$1.50</td>
<td>$2.00</td>
</tr>
<tr>
<td>Ryan Pfingst</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$1.10</td>
<td>$1.40</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.80</td>
<td>$2.50</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$1.40</td>
<td>$1.60</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Tom Curran</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Sell</td>
<td>$1.00</td>
<td>-</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$2.50</td>
<td>$2.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Plug Power. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Plug Power compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>For valuable insights into Plug Power's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PLUG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Plug Power analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Get to Know Plug Power Better</h2>
<p>Plug Power is building an end-to-end green hydrogen ecosystem-from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.</p>
<h3>Financial Milestones: Plug Power's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Plug Power's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-13.81%</strong>. This indicates a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Plug Power's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-697.46%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Plug Power's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-56.07%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Plug Power's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-32.07%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.62</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PLUG

10 Analysts Assess Plug Power: What You Need To Know

<p>Analysts' ratings for VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $5.75, along with a high estimate of $5.75 and a low estimate of $5.75. The average price target has stayed the same, reflecting a consistent view from analysts. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741287737_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive VYNE Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.75</td>
<td>$5.75</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.75</td>
<td>$5.75</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.75</td>
<td>$5.75</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.75</td>
<td>$5.75</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.75</td>
<td>$5.75</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to VYNE Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of VYNE Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for VYNE Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of VYNE Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VYNE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on VYNE Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About VYNE Therapeutics</h2>
<p>VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.</p>
<h3>Unraveling the Financial Story of VYNE Therapeutics</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> VYNE Therapeutics displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>6.14%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> VYNE Therapeutics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-10047.11%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> VYNE Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-17.57%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-14.93%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.0</strong>, VYNE Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


VYNE

VYNE Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

<p>Across the recent three months, 17 analysts have shared their insights on Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Kroger and provided 12-month price targets. The average target is $69.06, accompanied by a high estimate of $75.00 and a low estimate of $61.00. This upward trend is apparent, with the current average reflecting a 2.75% increase from the previous average price target of $67.21.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741287728_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Kroger. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$73.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$73.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$73.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>John Heinbockel</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$71.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Leah Jordan</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$61.00</td>
<td>-</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$65.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Ken Goldman</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Robert Ohmes</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>John Heinbockel</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$68.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$63.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Kroger. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Kroger compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Kroger's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Kroger's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/KR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Kroger analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Kroger</h2>
<p>Kroger is one of the largest grocery retailers in the United States with more than 2,700 stores across a portfolio of over 20 supermarket banners. The company boasts an ingrained presence in US communities, citing that it is a top-two grocer in most of its major market areas. Over one fourth of Kroger's roughly $110 billion in nonperishable and fresh food sales (about 75% of revenue) stems from its private-label portfolio, of which the company manufactures about 30% of units via its own food production plants. The firm also operates fuel stations and pharmacies at 60% and 80% of its locations, respectively.</p>
<h3>Financial Milestones: Kroger's Journey</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Challenges:</strong> Kroger's revenue growth over 3 months faced difficulties. As of 31 October, 2024, the company experienced a decline of approximately <strong>-0.95%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Kroger's net margin excels beyond industry benchmarks, reaching <strong>1.84%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Kroger's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>4.86%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Kroger's ROA excels beyond industry benchmarks, reaching <strong>1.09%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Kroger's debt-to-equity ratio surpasses industry norms, standing at <strong>2.31</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down Kroger: 17 Analysts Share Their Views

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Western Digital</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with WDC, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Western Digital.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 80% bullish and 13%, bearish.</p>
<p>Out of all of the special options we uncovered, 11 are puts, for a total amount of $491,200, and 4 are calls, for a total amount of $126,026.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $42.5 to $50.0 for Western Digital over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Western Digital's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Western Digital's whale activity within a strike price range from $42.5 to $50.0 in the last 30 days. </p>
<h3>Western Digital Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741287722_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>WDC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.05</td>
<td>$3.95</td>
<td>$4.0</td>
<td>$42.50</td>
<td>$76.4K</td>
<td align="right">1</td>
<td>1.8K</td>
</tr>
<tr>
<td>WDC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.05</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$42.50</td>
<td>$72.4K</td>
<td align="right">1</td>
<td>1.8K</td>
</tr>
<tr>
<td>WDC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.1</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$42.50</td>
<td>$54.4K</td>
<td align="right">1</td>
<td>209</td>
</tr>
<tr>
<td>WDC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.35</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$42.50</td>
<td>$53.2K</td>
<td align="right">1</td>
<td>441</td>
</tr>
<tr>
<td>WDC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.05</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$42.50</td>
<td>$44.0K</td>
<td align="right">1</td>
<td>902</td>
</tr>
</tbody>
</table>
</p>
<h3>About Western Digital</h3>
<p>Western Digital is a leading, vertically integrated supplier of hard disk drives. The HDD market is a practical duopoly with, Western Digital and Seagate being the two largest players. Western Digital designs and manufacturers its HDDs, with much of the manufacturing and workforce located in Asia. The primary consumers of HDDs are data centers.</p>
<p>Having examined the options trading patterns of Western Digital, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Western Digital Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 4,941,931, the WDC's price is down by -4.84%, now at $42.06. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 49 days.</li>
</ul>
<h3>Professional Analyst Ratings for Western Digital</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $86.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Western Digital, which currently sits at a price target of $75.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $95.<br />
&#x2A; An analyst from Wedbush has revised its rating downward to Outperform, adjusting the price target to $95.<br />
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $95.<br />
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Western Digital with a target price of $74. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Western Digital, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Western Digital Unusual Options Activity

<p>Financial giants have made a conspicuous bearish move on EQT. Our analysis of options history for EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) revealed 15 unusual trades.</p>
<p>Delving into the details, we found 20% of traders were bullish, while 66% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $1,185,722, and 6 were calls, valued at $243,408.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $33.0 to $50.0 for EQT during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of EQT stands at 2011.0, with a total volume reaching 7,840.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in EQT, situated within the strike price corridor from $33.0 to $50.0, throughout the last 30 days.</p>
<h3>EQT Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741287716_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>EQT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.02</td>
<td>$1.97</td>
<td>$2.0</td>
<td>$45.00</td>
<td>$332.6K</td>
<td>2.9K</td>
<td>1.6K</td>
</tr>
<tr>
<td>EQT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.5</td>
<td>$1.39</td>
<td>$1.5</td>
<td>$33.00</td>
<td>$316.8K</td>
<td>2.3K</td>
<td>2.1K</td>
</tr>
<tr>
<td>EQT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$3.35</td>
<td>$3.35</td>
<td>$3.35</td>
<td>$45.00</td>
<td>$293.4K</td>
<td>4.2K</td>
<td>0</td>
</tr>
<tr>
<td>EQT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.45</td>
<td>$5.4</td>
<td>$5.43</td>
<td>$45.00</td>
<td>$70.3K</td>
<td>1.1K</td>
<td>337</td>
</tr>
<tr>
<td>EQT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$3.3</td>
<td>$3.25</td>
<td>$3.25</td>
<td>$50.00</td>
<td>$65.0K</td>
<td>6.0K</td>
<td>249</td>
</tr>
</tbody>
</table>
</p>
<h3>About EQT</h3>
<p>EQT is an independent natural gas production company. It focuses its operations in the cores of the Marcellus and Utica shales, located in the Appalachian Basin in the Eastern United States. Its main customers include marketers, utilities, and industrial operators in the Appalachian Basin. The company has three reportable segments in production, gathering, and the transmission segment, which is now an operated joint venture with Blackstone. All the firm's operating revenue is generated in the US, with most revenue flowing from the Marcellus Shale field and through the sale of natural gas.</p>
<p>Following our analysis of the options activities associated with EQT, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of EQT</h3>
<ul>
<li>Trading volume stands at 6,471,656, with EQT's price down by -7.42%, positioned at $46.41.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 47 days.</li>
</ul>
<h3>Professional Analyst Ratings for EQT</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $54.4.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on EQT, which currently sits at a price target of $58.<br />
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on EQT with a target price of $66.<br />
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on EQT with a target price of $54.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Neutral rating for EQT, targeting a price of $36.<br />
&#x2A; An analyst from UBS has decided to maintain their Neutral rating on EQT, which currently sits at a price target of $58. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for EQT, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


EQT Unusual Options Activity For March 06

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>SiTime</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SITM#NASDAQ">SITM</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SITM, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 18 uncommon options trades for SiTime.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 61% bullish and 27%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $143,925, and 14 are calls, for a total amount of $1,160,112.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $240.0 for SiTime over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for SiTime's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across SiTime's significant trades, within a strike price range of $150.0 to $240.0, over the past month.</p>
<h3>SiTime Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741287711_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SITM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$40.1</td>
<td>$36.7</td>
<td>$39.0</td>
<td>$150.00</td>
<td>$273.0K</td>
<td align="right">75</td>
<td align="right">70</td>
</tr>
<tr>
<td>SITM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$11.4</td>
<td>$11.3</td>
<td>$11.3</td>
<td>$210.00</td>
<td>$169.0K</td>
<td align="right">17</td>
<td align="right">201</td>
</tr>
<tr>
<td>SITM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$50.3</td>
<td>$47.0</td>
<td>$49.0</td>
<td>$150.00</td>
<td>$117.6K</td>
<td align="right">75</td>
<td align="right">71</td>
</tr>
<tr>
<td>SITM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$6.7</td>
<td>$4.6</td>
<td>$5.02</td>
<td>$210.00</td>
<td>$102.4K</td>
<td align="right">17</td>
<td align="right">563</td>
</tr>
<tr>
<td>SITM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$12.7</td>
<td>$9.3</td>
<td>$9.3</td>
<td>$190.00</td>
<td>$102.3K</td>
<td align="right">10</td>
<td align="right">787</td>
</tr>
</tbody>
</table>
</p>
<h3>About SiTime</h3>
<p>SiTime Corp is a provider of silicon timing systems solutions. The company designs develops and sell silicon timing systems solutions for different industries including automotive, infrastructure, aerospace-defense, consumer, internet of things, consumer and industrials. Its product offerings include Stratum 3E DCOCXOs, Programmable OCXOs, MHz Oscillators, 32.768 kHz Oscillators, Embedded Resonators, Precision MHz Super-TCXOs, and Ruggedized Oscillators. It sells its products around Taiwan, Hong Kong, the United States, and other regions and generates the majority of its revenue from Taiwan.</p>
<p>Following our analysis of the options activities associated with SiTime, we pivot to a closer look at the company's own performance.</p>
<h3>SiTime's Current Market Status</h3>
<ul>
<li>With a volume of 579,712, the price of SITM is down -0.49% at $181.3. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 62 days.</li>
</ul>
<h3>What The Experts Say On SiTime</h3>
<p>In the last month, 3 experts released ratings on this stock with an average target price of $256.67.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Raymond James has revised its rating downward to Outperform, adjusting the price target to $250.<br />
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on SiTime with a target price of $250.<br />
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on SiTime, which currently sits at a price target of $270. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest SiTime options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


SITM

Behind the Scenes of SiTime's Latest Options Trends

<p>HC Wainwright &amp; Co.  analyst Joseph Pantginis   reiterates VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) with a Buy and maintains $5.75 price target.</p>


HC Wainwright & Co. Reiterates Buy on VYNE Therapeutics, Maintains $5.75 Price Target

<p>HC Wainwright &amp; Co.  analyst Vernon Bernardino   reiterates Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) with a Buy and maintains $10 price target.</p>


ENVB

HC Wainwright & Co. Reiterates Buy on Enveric Biosciences, Maintains $10 Price Target

<p><a href="https://www.bloomberg.com/news/articles/2025-03-06/openai-oracle-eye-nvidia-chips-worth-billions-for-stargate-site" title="https://www.bloomberg.com/news/articles/2025-03-06/openai-oracle-eye-nvidia-chips-worth-billions-for-stargate-site">https://www.bloomberg.com/news/articles/2025-03-06/openai-oracle-eye-nvidia-chips-worth-billions-for-stargate-site</a></p>


Tech

MSFT

NVDA

ORCL

Bloomberg: 'OpenAI, Oracle Eye Nvidia Chips Worth Billions for Stargate Site'

CK Hutchison Holdings

<p>국무장관 <strong><a href="https://www.benzinga.com/topic/marco-rubio" target="_blank" rel="noreferrer noopener">마코 루비오</a></strong>의 파나마 방문은 <a href="https://www.benzinga.com/topic/marco-rubio" target="_blank" rel="noreferrer noopener">트럼프 행정부 하에서</a> 미국 외교 정책, 특히 라틴 아메리카에 대한 방향성에 중요한 통찰을 제공할 것으로 예상된다.</p>
<p>파나마 운하를 둘러싼 긴장이 고조되는 가운데, 이번 방문은 미국 정책이 보다 공격적이고 제국주의적인 접근을 취할 것인지, 아니면 실용적이고 협상 중심의 입장을 취할 것인지를 신호할 수 있다고 로이터 통신이 보도했다.</p>
<p>이 논란은 <strong>트럼프 대통령</strong>이 파나마의 운하 통제에 대해 위협적인 발언을 하면서 시작되었으며, 이는 잠재적인 미국 침공에 대한 우려를 불러일으켰다. 전 파나마 대통령인 <strong>에르네스토 페레스바야다레스</strong>(Ernesto Pérez Balladares)는 미국의 공격이 격화될 경우 큰 인명 피해와 국제적 비난이 발생할 수 있다고 우려를 표명했다.</p>
<p>이러한 고조된 수사에도 불구하고, 트럼프의 라틴 아메리카 특사인 <strong>마우리시오 클라버 캐론</strong>(Mauricio Claver-Carone)은 파나마가 미 해군과 해안경비대에 운하 통행료를 면제해 주는 제안을 사전에 제공함으로써 추가적인 긴장을 피할 수 있다고 제안했다고 로이터가 추가 보도했다.</p>
<p><em><strong>추가 읽기: <a href="https://kr.benzinga.com/news/usa/economy/%ED%8A%B8%EB%9F%BC%ED%94%84-2%EC%9B%94-1%EC%9D%BC%EB%B6%80%ED%84%B0-%EC%BA%90%EB%82%98%EB%8B%A4-%EB%A9%95%EC%8B%9C%EC%BD%94-%EB%B0%8F-%EC%A4%91%EA%B5%AD-%EC%A0%9C%ED%92%88%EC%97%90-%EB%8C%80/" target="_blank" rel="noopener">트럼프, 캐나다, 멕시코, 중국산 제품에 새로운 관세 부과 발표: 2월 1일부터 발효</a></strong></em></p>
<p>이러한 노력에도 불구하고, 미국-파나마 관계의 미래에 대한 불확실성은 여전히 존재다.</p>
<p>파나마 정부 관계자들은 중국 군사력이 운하에 존재한다는 트럼프의 주장을 사적으로 일축하며, 통행료는 법적으로 설정되어 모든 국가에 적용된다고 강조했다.</p>
<p>파나마의 정치 엘리트는 운하의 지위가 협상 대상이 아님을 분명히 했으며, <strong>호세 라울 물리노</strong> 대통령은 1999년 미국으로부터 반환된 수로에 대한 파나마의 주권을 강력히 방어했다.</p>
<p>트럼프의 위협에 대응하여, 파나마는 홍콩 기반의 <strong>CK 허치슨 홀딩스 LTD</strong>(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CKHUY#OTC">CKHUY</a>)가 관리하는 항구 운영에 대한 감사를 강화하는 등 일부 화해 조치를 취했다.</p>
<p>하지만 이러한 조치는 외교적 폭풍을 진정시키는 데에는 거의 도움이 되지 않았다. 트럼프 행정부 내에서 일부는 수사를 문자 그대로 받아들이지 말아야 한다고 제안하는 반면, 다른 이들은 여전히 지역 내 미국의 지배력을 주장하는 데 확고한 입장을 유지하고 있다.</p>
<p>루비오가 파나마를 방문 준비를 하면서, 외교가 상황을 완화시킬 수 있다는 희망의 빛이 있다.</p>
<p>최근 미국 국무부는 파나마와의 협력적 관계를 조성하려는 방향으로 전환하고, 강력한 파트너십의 상호 이점을 강조하는 데 중점을 두었다고 밝혔다. 일방적인 압박을 행사하려는 시도는 지양한 것이다.</p>
<p>결국, 루비오의 방문은 트럼프 행정부가 공격적인 수사와 실용적인 외교를 조화롭게 유지할 수 있는지를 시험하는 중요한 기회가 될 것이며, 미국의 이익과 파나마의 주권이 앞으로도 존중받도록 할 수 있는지를 판별할 중요한 시험대가 될 것이다.</p>
<p class="block core-block">
<p><em><strong>다음 읽기:</strong></em></p>
<ul>
<li><a href="https://kr.benzinga.com/news/usa/economy/%EC%9D%BC%EB%A1%A0-%EB%A8%B8%EC%8A%A4%ED%81%AC%EC%9D%98-%EB%B3%B4%EC%A2%8C%EC%A7%84-%EA%B3%B5%EB%AC%B4%EC%9B%90%EB%93%A4%EC%9D%98-%EC%97%B0%EB%B0%A9-%EB%8D%B0%EC%9D%B4%ED%84%B0-%EC%8B%9C%EC%8A%A4/" target="_blank" rel="noopener"><em><strong>일론 머스크의 보좌진이 정부 직원들을 연방 데이터 시스템에서 차단함: 보도</strong></em></a></li>
</ul>
<p><strong>Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요</strong><br />
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요.<br />
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener"><strong>여기를 클릭</strong></a>하여 14일 무료 체험을 시작하세요.</p>

Comments

CK Hutchison Holdings

뉴스

에 대한 최신 뉴스 CK Hutchison Holdings (OTC:CKHUY) 주식

일요일, 2월 02, 2025

뉴스

파트너 / 기고자

벤징가 글로벌